Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 20/20 | 1.00 |
| ▸ | ABL1 | P00519 | 11/20 | 1.00 |
| ▸ | ABL2 | P42684 | 9/20 | 1.00 |
| ▸ | BCR | P11274 | 3/20 | 0.77 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.77 |
| ▸ | STK25 | O00506 | 1/20 | 0.77 |
| ▸ | CIT | O14578 | 1/20 | 0.77 |
| ▸ | RIOK3 | O14730 | 1/20 | 0.77 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.77 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.77 |
| ▸ | CASK | O14936 | 1/20 | 0.77 |
| ▸ | GAK | O14976 | 1/20 | 0.77 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.77 |
| ▸ | MAP3K13 | O43283 | 1/20 | 0.77 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.77 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.77 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.77 |
| ▸ | JAK2 | O60674 | 1/20 | 0.77 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.77 |
| ▸ | ULK1 | O75385 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30453491 | 1.00 | SRC (1.00) | SRCABL1ABL2BCRKCNH2 | |
| SCHEMBL30453438 | 0.96 | SRC (0.92) | SRCABL1ABL2BCRKCNH2 | |
| SCHEMBL676580 | 0.96 | SRC (0.92) | SRCABL1ABL2BCRKCNH2 | |
| SCHEMBL675968 | 0.96 | SRC (1.00) | SRCABL1ABL2BCRKCNH2 | |
| SCHEMBL30454332 | 0.96 | SRC (1.00) | SRCABL1ABL2BCRKCNH2 | |
| SCHEMBL30453888 | 0.93 | SRC (1.00) | SRCABL1ABL2BCRKCNH2 | |
| SCHEMBL676581 | 0.93 | SRC (1.00) | SRCABL1ABL2BCRKCNH2 | |
| SCHEMBL30452986 | 0.92 | SRC (0.93) | SRCABL1ABL2BCRKCNH2 | |
| SCHEMBL677192 | 0.92 | SRC (0.93) | SRCABL1ABL2BCRKCNH2 | |
| SCHEMBL6183462 | 0.91 | SRC (0.89) | SRCABL1ABL2BCRKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3002009-A2 | TREATMENT OF IMATINIB RESISTANT LEUKEMIA USING 4-AMINOQUINOLINE-3-CARBONITRILES | Wyeth LLC (US) | 2016-04-06 | — | — | EP | claimed |
| EP-2777704-A2 | Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles | Wyeth LLC (US) | 2014-09-17 | — | — | EP | claimed |
| EP-2478905-A2 | Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles | Wyeth LLC (US) | 2012-07-25 | — | — | EP | claimed |
| US-20100029677-A1 | 4-ANILINO-3-QUINOLINECARBONITRILES FOR THE TREATMENT OF CHRONIC MYELOGENOUS LEUKEMIA (CML) | WYETH (US) | 2010-02-04 | — | — | US | claimed |
| US-20080318971-A1 | using bosutinib | WYETH (US) | 2008-12-25 | — | — | US | claimed |
| US-7468379-B2 | Inhibition of osteolytic lesions by SRC kinase inhibitors | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-12-23 | — | — | US | claimed |
| US-7417148-B2 | 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML) | WYETH (US) | 2008-08-26 | — | — | US | claimed |
| EP-1896020-A1 | INHIBITION OF OSTEOLYTIC LESIONS BY SRC KINASE INHIBITORS | The Board of Regents of The University of Texas System (US) | 2008-03-12 | — | — | EP | claimed |
| US-20070004748-A1 | Inhibition of osteolytic lesions by SRC kinase inhibitors | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2007-01-04 | — | — | US | claimed |
| WO-2006138590-A1 | INHIBITION OF OSTEOLYTIC LESIONS BY SRC KINASE INHIBITORS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2006-12-28 | — | — | WO | claimed |
| EP-1499594-B1 | PROCESS FOR THE PREPARATION OF 7-SUBSTITUTED-3-QUINOLINE AND 3-QUINOL-4-ONE CARBONITRILES | WYETH CORP (US) | 2005-08-17 | — | — | EP | claimed |
| WO-2005047259-A1 | 4-ANILINO-3-QUINOLINECARBONITRILES FOR THE TREATMENT OF CHRONIC MYELOGENOUS LEUKEMIA (CML) | WYETH (US) | 2005-05-26 | — | — | WO | claimed |
| WO-2005046693-A1 | 4-ANILINO-3-QUINOLINECARBONITRILES FOR THE TREATMENT OF CHRONIC MYELOGENOUS LEUKEMIA (CML) | WYETH (US) | 2005-05-26 | — | — | WO | claimed |
| US-20050101780-A1 | 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML) | WYETH (US) | 2005-05-12 | — | — | US | claimed |
| EP-1499594-A1 | PROCESS FOR THE PREPARATION OF 7-SUBSTITUTED-3-QUINOLINE AND 3-QUINOL-4-ONE CARBONITRILES | Wyeth Holdings Corporation (US) | 2005-01-26 | — | — | EP | claimed |
| US-20040229880-A1 | 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury | WYETH | 2004-11-18 | — | — | US | claimed |
| WO-2004075898-A1 | 4-[(2,4-DICHLORO-5-METHOXYPHENYL)AMINO]-6-ALKOXY-3-QUINOLINECARBONITRILES FOR THE TREATMENT OF ISCHEMIC INJURY | WYETH (US) | 2004-09-10 | — | — | WO | claimed |
| US-6780996-B2 | KINASE INHIBITORS; ANTICANCER AGENTS | WYETH HOLDINGS CORPORATION | 2004-08-24 | — | — | US | claimed |
| US-20030212276-A1 | Process for the preparation of 7-substituted-3 quinolinecarbonitriles | WYETH HOLDINGS CORPORATION | 2003-11-13 | — | — | US | claimed |
| WO-2003093241-A1 | PROCESS FOR THE PREPARATION OF 7-SUBSTITUTED-3-QUINOLINE AND 3-QUINOL-4-ONE CARBONITRILES | WYETH HOLDINGS CORPORATION (US) | 2003-11-13 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212276-A1 | Process for the preparation of 7-substituted-3 quinolinecarbonitriles | MAP4K2, MAP3K7, MAP4K1 | SRC 386/4885ABL1 26/4885ABL2 440/4885 |
| US-20070004748-A1 | Inhibition of osteolytic lesions by SRC kinase inhibitors | SRC, CAMK1, SOST | SRC 1/4885ABL1 1351/4885ABL2 2090/4885 |
| US-20040229880-A1 | 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury | TNNI3, TXN2, AIFM1 | SRC 4373/4885ABL1 655/4885ABL2 1620/4885 |
| US-20050101780-A1 | 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML) | ABL1, MCL1, NPM1 | SRC 244/4885ABL1 1/4885ABL2 8/4885 |
| US-20080318971-A1 | using bosutinib | ABL1, BCR, MCL1 | SRC 345/4885ABL1 1/4885ABL2 11/4885 |
| US-20100029677-A1 | 4-ANILINO-3-QUINOLINECARBONITRILES FOR THE TREATMENT OF CHRONIC MYELOGENOUS LEUKEMIA (CML) | ABL1, MCL1, NPM1 | SRC 244/4885ABL1 1/4885ABL2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.